Status:
RECRUITING
Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial
Lead Sponsor:
Clinical Urology and Epidemiology Working Group
Collaborating Sponsors:
Helsinki University Central Hospital
University of Helsinki
Conditions:
Venous Thromboembolism
Bleeding
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Avoiding Risks of Thrombosis and bleeding in Surgery (ARTS) trial is a pragmatic, international, multicenter, randomized controlled open label trial comparing a direct oral anticoagulant (DOAC) - oral...
Detailed Description
Deep vein thrombosis and pulmonary embolism - collectively known as venous thromboembolism VTE - and major bleeding are serious surgical complications leading to poorer patient-reported quality of lif...
Eligibility Criteria
Inclusion
- Informed consent provided
- Adult patients (≥18 years);
- Undergoing elective abdominal or pelvic surgery at similar (and not high) risk of VTE and bleeding
Exclusion
- Inability to provide informed consent
- Patient with active bleeding/hemorrhage during the last 6 months if not expected to be treated by surgery planned
- Lesion or condition if considered a significant risk factor for major bleeding
- a. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
- Anticoagulant treatment, antiplatelet treatment or omega-3 dietary supplement during previous 7 days preceding surgery and/or requiring within 30 days post-surgery
- Patient who had during previous 6 months or are expected require within 30 days post-surgery chemotherapy/radiation or hormone therapy for cancer
- Known thrombophilia
- Known bleeding disorder
- Substantial liver impairment (for instance INR 1.4 or more during last 60 days)
- eGRF \<30 mL/min/1.73 m2
- Platelet count \<100 × 109/L (that is, 100 000 mg/L)
- Hb \<90 g/L (that is, \<9 g/dL)
- ALT \>2 × upper limit of normal
- Known allergy to apixaban
- Taking strong inhibitors or inductors of both CYP 3A4 and P-glycoprotein, such as anti-seizure medications (e.g. phenytoin, fosphenytoin, carbamazepine), azole-antimycotics (e.g. ketoconazole, itraconazole), HIV-protease inhibitors (e.g. ritonavir, indinavir) and rifampicin
- Concomitant procedures with high risk of VTE/bleeding
- Previous VTE
- Pregnant or breast-feeding female patients
- Female participants who have had periods in the last 12 months and who are not using highly reliable contraception: (i) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); ii) progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); iii) intrauterine device (IUD); iv) intrauterine hormone-releasing system (IUS); v) bilateral tubal occlusion; vi) vasectomized partner; and vii) sexual abstinence from heterosexual intercourse during the entire period of risk associated with the study treatments
- Previous randomization in this trial
- Any reason why, in the opinion of the investigator(s), the patient should not participate
Key Trial Info
Start Date :
June 6 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
5436 Patients enrolled
Trial Details
Trial ID
NCT06523959
Start Date
June 6 2024
End Date
December 31 2028
Last Update
May 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Hospital
Helsinki, Finland, 00029